Bristol-Myers Squibb Company
New York Stock Exchange•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.Company Description
- CEO
- Christopher S. Boerner
- Full Time Employees
- 34,100
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Address
- 430 East 29th Street Princeton NY United States of America 10016
- IPO Date
- Jun 1, 1972
- CIK
- 0000014272
- Website
- bms.com
- Similar Companies
- Business
- Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; and Orencia for adult patients with active RA and psoriatic arthritis. It also provides Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Abraxane, a protein-bound chemotherapy product; Reblozyl for the treatment of anemia in adult patients with beta thalassemia; and Empliciti for the treatment of multiple myeloma. In addition, the company offers Zeposia to treat relapsing forms of multiple sclerosis; Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma; Inrebic, an oral kinase inhibitor indicated for the treatment of adult patients with myelofibrosis; and Onureg for the treatment of adult patients with AML. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in New York, New York.
Company News
Bristol Myers, Pfizer to sell blood thinner Eliquis directly to patients
Bristol Myers Squibb and Pfizer Announce Direct-to-Patient Eliquis® (apixaban) Option
Bristol-Myers Squibb and Pfizer plan to sell the widely used blood thinner Eliquis directly to patients at a discounted cash price
Will Increased Expenses Affect Bristol Myers' Performance?
Is Bristol-Myers Squibb Still An Undervalued Biopharma Play?
$7.4 Trillion Is in Money Markets Now: When Rates Fall, These High-Yield Blue Chips Will Run
ABBV or BMY: Which Biopharma Giant Has Better Prospects for Now?
2 Top Stocks Down 16% and 17% This Year to Buy and Hold
Dividend Harvesting Portfolio Week 227: $22,700 Allocated, $2,385.24 In Projected Dividends
Bristol Myers Squibb: Hidden Facts Blur The Strength Of The Company
Bristol Myers Squibb (BMY) Surpasses Market Returns: Some Facts Worth Knowing
Will Recent Label Expansions of Opdivo Help BMY Gain Momentum?
June Readers Tagged 13 Ideal Dividend Dogs From 16 "Safer" Out Of 38 ReFa/Ro
Healthy Returns: Medicaid cuts in Trump's megabill may affect some drugmakers more than others
2 Wonderful Dividends At Bargain Basement Prices
Investors Heavily Search Bristol Myers Squibb Company (BMY): Here is What You Need to Know
Boomers Are Grabbing These Big Beautiful Blue-Chip Dividend Giants For Decades of Passive Income
Will The Decline in Legacy Drugs Pull Down BMY's Top Line?
Bristol Myers Squibb (BMY) Ascends While Market Falls: Some Facts to Note
Bristol-Myers Squibb: Strong Launch Portfolio Amid Market Reset